Efficacy of different devices for transcatheter closure of XXXX assessed by serial transoesophageal echocardiography and rates of recurrent cerebrovascular events in a long-term follow-up.

@entity1 @entity64 @entity439 @entity418 @entity4616
UNASSIGNED: Aims: Closure of @entity4616 ( @entity4616 ) is non-inferior to medical treatment for @entity1 with cryptogenic @entity64 . Results in randomised trials might be based on the different types of used occluders. We determined residual shunting with serial contrast transoesophageal echocardiography (cTEE) and evaluated rates of recurrent cerebrovascular events in a long-term follow-up. Methods and results: cTEE was repeated three and 12 months after @entity4616 closure using AMPLATZER (n=109), BioSTAR (n=68), @entity418 (n=104) or Premere (n=54) occluders. Closure was demonstrated in 91.6% and 95.9% of @entity1 after three and 12 months. Closure rates were not different among groups (p=0.58; p=0.94). The @entity4616 diameter was a risk factor for residual shunting (p=0.02), but not the prevalence of an @entity439 ( @entity439 ). During follow-up, including 1,815 @entity1 -years (PY), eight @entity1 suffered a @entity64 (0.44/100 PY) and seven @entity1 a transient ischaemic attack (0.39/100 PY). Rates of recurrent cerebrovascular events were similar among the four groups. Conclusions: Closure at three or 12 months (as measured by cTEE) and rates of recurrent cerebrovascular events were similar among occluder groups. @entity4616 diameter was a risk factor for residual shunting, but not the presence of @entity439 . The rate of recurrent cerebral ischaemic events was low.
